From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Biologics Before Chemotherapy: Treatment Updates for Mycosis Fungoides, Sézary Syndrome

The use of chemotherapy to treat mycosis fungoides and Sézary syndrome, the most common forms of cutaneous T-cell lymphomas, led to a shorter time...
WIB_icon

Off-Label Rituximab Proves Its Mettle in Adult ITP

For adult patients with persistent or chronic immune thrombocytopenia (ITP), off-label treatment with rituximab proved a safe and effective management option, according to results...
WIB_icon

Pre-Procedure Anticoagulation Interruption May Not Be Necessary

Patients with atrial fibrillation (AF) on anticoagulation therapies who require a surgical procedure may require an interruption in the therapy – depending on their...
WIB_icon

Obesity Has Early and Lasting Effects on Children with ALL

For children with B-precursor acute lymphocytic leukemia (BP-ALL), having a BMI ≥30 kg/m2 at the time of treatment initiation more than doubled the likelihood...
WIB_icon

MPL Expression Necessary for Development of Jak2V617F-Induced MPN

Results of a preclinical study showed that ablating the thrombopoietin (TPO) receptor (MPL) in Jak2V617F-positive mice prevented the development of myeloproliferative neoplasms (MPNs). The...
WIB_icon

Remission Duration Key to Survival in CLL After FCR

In spite of the efficacy of the treatment regimen of fludarabine, cyclophosphamide, and rituximab (FCR) in chronic lymphocytic leukemia (CLL), most CLL patients are...
WIB_icon

Once-Weekly Bortezomib Produced Durable Responses, Survival in Relapsed AL Amyloidosis

Results from a phase I/II study of single-agent bortezomib suggest that a once-weekly dosing regimen produced similar efficacy results to a twice-weekly regimen —...
WIB_icon

The Earlier the Better Early Response to Imatinib Predicted Outcomes in Children with CML

While imatinib has been proven effective for the majority of pediatric patients with chronic myeloid leukemia (CML), 13 to 25 percent of children still...
WIB_icon

Moderate-Dose Cyclophosphamide for Severe Aplastic Anemia:Potential Toxicity Outweighs Potential Benefit

While cyclophosphamide at high or more moderate doses can be active in severe aplastic anemia, a new study published in Blood reveals that a...
WIB_icon

New Target Holds Potential for Treatment of Common Anemia

Lexaptepid, an anti-hepcidin therapy, may be the first viable treatment option for patients with anemia of inflammation, according to the results of an experimental...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.